http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101614157-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-61 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36 |
| filingDate | 2006-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101614157-B1 |
| titleOfInvention | Antitumoral bioconjugates of hyaluronic acid or its derivatives obtained by indirect chemical conjugation |
| abstract | The present invention relates to novel bioconjugate groups obtainable by indirect synthesis between hyaluronic acid and / or its derivatives and drugs having anticancer activity belonging to different groups via a molecular spacer, their preparation and their use in the field of tumors Describe their use. The novel derivatives have different physicochemical properties, in terms of their binding type and substitutional properties, which improve the tolerability and efficacy of these derivatives and provide a more precise dosage control using the active targeting mechanism . |
| priorityDate | 2005-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 77.